Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration.
OBJECTIVE
To evaluate an intravenous meropenem dosage regimen in adult intensive care patients with acute renal failure treated by continuous renal replacement therapy.


METHODS
A prospective, clinical study.


METHODS
General intensive care unit of a university hospital.


METHODS
Ten critically ill adult patients being treated with meropenem and receiving continuous veno-venous hemofiltration (hemofiltration rates, 1-2 L/hr) (n = 5) or continuous venovenous hemodiafiltration (hemofiltration rates, 1-1.5 L/hr; dialysis rates, 1-1.5 L/hr) (n = 5) via a polyacrylonitrile hollow fiber 0.9-m2 filter.


METHODS
Patients received a meropenem dose of 1 g iv every 12 hrs as a 5-min bolus.


RESULTS
Meropenem concentrations were measured by high-performance liquid chromatography in serum taken at timed intervals and in ultrafiltrate/dialysate to determine serum concentration-time profiles, derive pharmacokinetic variable estimates, and determine sieving coefficients and filter clearances. The serum concentrations were examined to see whether they were above the minimum inhibitory concentrations (MICs) for pathogens that may be encountered in intensive care patients. Serum concentrations exceeded 4 mg/L (MIC90 for Pseudomonas aeruginosa) during 67% of the dosage period in all patients. Sub-MIC90 concentrations were obtained in three patients immediately before treatment and in one patient 12 hrs after treatment. Mean (SD) (n = 10) pharmacokinetic variable estimates were as follows: elimination half-life, 5.16 hrs (1.83 hrs); volume of distribution, 0.35 L/kg (0.10 L/kg); and total clearance, 4.30 L/hr (1.38 L/hr). A sieving coefficient of 0.93 (0.06) (n = 9) indicated free flow across the filter. The fraction cleared by the extracorporeal route was 48% (13%) (n = 9), which is clinically important.


CONCLUSIONS
A meropenem dose of 1g iv every 12 hrs provides adequate serum concentrations in the majority of patients receiving continuous veno-venous hemofiltration or continuous venovenous hemofiltration with a 0.9-m2 polyacrylonitrile filter at combined ultrafiltrate/dialysate flow rates of up to 3 L/hr. A lower dose would not be sufficient for the empirical treatment of potentially life-threatening infections in all patients.
Giles
L J
LJ
Guy's and St. Thomas Hospital Trust, St. Thomas Hospital, London, UK.
Jennings
A C
AC
Thomson
A H
AH
Creed
G
G
Beale
R J
RJ
McLuckie
A
A
D058186:Acute Kidney Injury / Q000382:microbiology* / Q000628:therapy; D000328:Adult; D000368:Aged; D003422:Critical Care; D005260:Female; D006207:Half-Life; D017583:Hemodiafiltration; D006440:Hemofiltration; D006801:Humans; D007275:Injections, Intravenous; D016014:Linear Models; D008297:Male; D000077731:Meropenem; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D011446:Prospective Studies; D018805:Sepsis / Q000150:complications / Q000188:drug therapy*; D013845:Thienamycins / Q000008:administration & dosage / Q000493:pharmacokinetics*
D013845:Thienamycins; D000077731:Meropenem